Company intelligence / Profile preview

Beijing Kangquanli Biotechnology

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Beijing Kangquanli Biotechnology is a clinical-stage biopharmaceutical company based in China, specializing in the development of innovative cell therapies for oncology and autoimmune disorders. The company focuses on advancing next-generation CAR-T cell therapies designed to improve safety and efficacy over existing treatments. Its lead programs target hematological malignancies such as B-cell lymphoma and multiple myeloma. Kangquanli Biotechnology leverages a proprietary technology platform to optimize cell persistence and reduce toxicity, aiming to provide more accessible and effective immunotherapy options for patients globally.

Therapeutic areas: OncologyImmunology
Modalities: Cell therapyCAR-T cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Beijing Kangquanli Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Kangquanli Biotechnology.

Explore the full profile